Compromised Behavior and Gamma Power During Working Memory in Cognitively Healthy Individuals With Abnormal CSF Amyloid/Tau

Roger Rochart, Quanying Liu, Alfred N. Fonteh, Michael G. Harrington, Xianghong ArakakiFrontiers in Aging Neuroscience 2020 · DOI

Abstract

Emerging research indicates that gamma-band oscillations are sensitive indicators of synaptic health and are significantly altered in the early stages of Alzheimer’s Disease (AD). This study aimed to determine if a cognitive "stress test"—combining an N-back working memory task with quantitative EEG (qEEG)—could unmask physiological abnormalities in individuals who are cognitively healthy (CH) but possess pathological cerebrospinal fluid (CSF) biomarkers for AD. We analyzed low (30–50 Hz) and high (50–80 Hz) gamma power across six brain regions in 24 participants stratified into normal (CH-NAT) and pathological (CH-PAT) groups based on amyloid/tau ratios. Our findings reveal a pattern of frontocentral hyperactivity during low-load tasks and a subsequent failure to maintain gamma power during high-load challenges in the CH-PAT group. These results suggest that gamma activity is a viable non-invasive marker for identifying individuals in the prodromal stage of AD.

Introduction

The "silent" phase of Alzheimer’s Disease, occurring years before clinical symptoms manifest, represents a critical window for therapeutic intervention. However, identifying individuals in this stage typically relies on invasive CSF draws or expensive PET imaging. There is an urgent need for functional, non-invasive markers that reflect the state of synaptic health. Gamma oscillations (30–80 Hz) are particularly promising as they are generated by the activity of inhibitory GABAergic interneurons, which are known to be vulnerable in the early stages of AD pathology. This study investigates whether the combination of a cognitive challenge and qEEG can reveal early functional deficits in the "at-risk" brain.

Methods

Participants and Stratification

The study cohort consisted of 24 cognitively healthy adults aged 60 and older. Participants were categorized based on their CSF amyloid-beta and tau protein ratios:

  • CH-NAT (Normal Amyloid/Tau): 10 participants with biomarker profiles within the normal range.
  • CH-PAT (Pathological Amyloid/Tau): 14 participants with biomarker profiles indicative of AD risk.

Cognitive Challenge: The N-back Task

Participants performed an N-back working memory task under two conditions:

  1. 0-back (Low Load): A simple target detection task where participants identified a specific letter.
  2. 2-back (High Load): A more demanding task requiring participants to determine if the current letter matched the one presented two steps prior.

qEEG Data Acquisition and Analysis

EEG data were recorded during the tasks, and power in the low gamma (30–50 Hz) and high gamma (50–80 Hz) bands was calculated using Morlet wavelet convolution. Analysis was conducted across six predefined regions: frontal, central, parietal, left temporal, right temporal, and occipital.

Results

Behavioral Performance and Cognitive Load

While both groups showed comparable performance on the 0-back task, a significant divergence emerged during the 2-back condition. The CH-PAT group exhibited significantly lower accuracy ($p = 0.029$, Cohen’s $d = -0.87$), suggesting that the presence of AD biomarkers is associated with impaired working memory performance when cognitive demand is high.

Gamma Power: Hyperactivity and Failure

The qEEG analysis revealed a distinct neurophysiological signature in the CH-PAT group. During the low-load 0-back task, CH-PATs showed significantly higher low-gamma power in frontocentral regions compared to CH-NATs ($p = 0.014 \sim 0.032$, Cohen’s $d = 0.95 \sim 1.11$). This likely represents a compensatory but inefficient over-recruitment of neural resources.

Topographic distribution of gamma power and statistical differences between CH-NAT and CH-PAT groups. Row B shows 0-back results; Row C shows 2-back results.

However, during the high-load 2-back task, this compensatory mechanism failed. The CH-PAT group showed significantly lower low-gamma power in the left temporal region ($p = 0.045$, Cohen’s $d = -0.96$) and lower high-gamma power in the parietal region ($p = 0.035$, Cohen’s $d = -1.02$). Across the entire scalp, the effect sizes for gamma power in the high-load condition were medium to large and negative (Cohen’s $d = -0.51 \sim -1.02$).

Time-frequency spectrograms illustrating the evolution of gamma power across different brain regions (F: Frontal, C: Central, P: Parietal, O: Occipital) during the task.

Brain-Behavior Coupling

In healthy aging (CH-NAT), gamma power during the 2-back task was strongly and positively correlated with 0-back accuracy ($r = 0.68 \sim 0.78$) and negatively correlated with response times. This suggests that in normal aging, the ability to modulate gamma power is directly linked to cognitive efficiency. In contrast, this vital brain-behavior coupling was significantly disrupted in the CH-PAT group.

Discussion

The findings of this study provide preliminary evidence that gamma power is compromised in AD-biomarker positive individuals who are otherwise cognitively healthy. The observed pattern—hyperactivity during simple tasks followed by a failure to maintain power during complex tasks—aligns with the theory that amyloid and tau pathology disrupt the excitatory/inhibitory (E/I) balance of neural circuits. The loss of correlation between gamma power and behavioral performance in the CH-PAT group further underscores the functional impact of these early pathological changes.

Conclusion

This pilot study highlights the potential of combining cognitive challenges with qEEG as a sensitive, non-invasive method for identifying individuals in the prodromal stage of Alzheimer’s Disease. While the small sample size necessitates further validation in larger, more diverse cohorts, these results encourage the development of neurophysiology-based markers to improve our understanding of AD pathophysiology and enhance early detection efforts.

Summary updated

Abstract

Research shows that gamma activity changes in Alzheimer's disease (AD), revealing synaptic pathology and potential therapeutic applications. We aim to explore whether cognitive challenge combined with quantitative EEG (qEEG) can unmask abnormal gamma frequency power in healthy individuals at high risk of developing AD. We analyzed low (30-50 Hz) and high gamma (50-80 Hz) power over six brain regions at EEG sensor level (frontal/central/parietal/left temporal/right temporal/occipital) in a dataset collected from an aging cohort during N-back working memory (WM) testing at two different load conditions (<i>N</i> = 0 or 2). Cognitively healthy (CH) study participants (≥60 years old) of both sexes were divided into two subgroups: <b>n</b>ormal <b>a</b>myloid/<b>t</b>au ratios (CH-NAT, <i>n</i> = 10) or <b>p</b>athological <b>a</b>myloid/<b>t</b>au (CH-PAT, <i>n</i> = 14) in cerebrospinal fluid (CSF). During low load (0-back) challenge, low gamma is higher in CH-PATs than CH-NATs over frontal and central regions (<i>p</i> = 0.014∼0.032, effect size (Cohen's <i>d</i>) = 0.95∼1.11). However, during high load (2-back) challenge, low gamma is lower in CH-PATs compared to CH-NATs over the left temporal region (<i>p</i> = 0.045, Cohen's <i>d</i> = -0.96), and high gamma is lower over the parietal region (<i>p</i> = 0.035, Cohen's <i>d</i> = -1.02). Overall, our studies show a medium to large negative effect size across the scalp (Cohen's <i>d</i> = -0.51∼-1.02). In addition, low gamma during 2-back is positively correlated with 0-back accuracy over all regions except the occipital region only in CH-NATs (<i>r</i> = 0.69∼0.77, <i>p</i> = 0.0098∼0.027); high gamma during 2-back correlated positively with 0-back accuracy over all regions in CH-NATs (<i>r</i> = 0.68∼0.78, <i>p</i> = 0.007∼0.030); high gamma during 2-back negatively correlated with 0-back response time over parietal, right temporal, and occipital regions in CH-NATs (<i>r</i> = -0.70∼-0.66, <i>p</i> = 0.025∼0.037). We interpret these preliminary results to show: (1) gamma power is compromised in AD-biomarker positive individuals, who are otherwise cognitively healthy (CH-PATs); (2) gamma is associated with WM performance in normal aging (CH-NATs) (most significantly in the frontoparietal region). Our pilot findings encourage further investigations in combining cognitive challenges and qEEG in developing neurophysiology-based markers for identifying individuals in the prodromal stage, to help improving our understanding of AD pathophysiology and the contributions of low- and high-frequency gamma oscillations in cognitive functions.
BibTeX
@inproceedings{rochart2020compromised,
  author = {Roger Rochart and Quanying Liu and Alfred N. Fonteh and Michael G. Harrington and Xianghong Arakaki},
  title = {{Compromised Behavior and Gamma Power During Working Memory in Cognitively Healthy Individuals With Abnormal CSF Amyloid/Tau}},
  booktitle = {Frontiers in Aging Neuroscience},
  year = {2020},
  doi = {10.3389/fnagi.2020.574214},
}
Figure